Biogen Idec (Nasdaq: BIIB) : BIIB & ELN's Tysabri for multiple sclerosis will be reviewed by an FDA Advisory Committee ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE